Regulonix is an early-stage biotechnology company developing non-opioid drugs for chronic pain. By indirectly targeting the sodium channel NaV1.7 – a well-established and genetically validated pain target – and focusing on the signaling pathways that control this channel’s activity, the Regulonix team has isolated compounds demonstrated in animal models to be non-addictive and more effective than morphine. 

Biotechnology

Regulonix Holding

Rajesh Khanna

Regulonix Holding's Leadership Team includes Rajesh Khanna.

Leadership Team

About

Team members